title: Psoralen photochemotherapy.
abstract: Psoralens and sunlight have been used by the Egyptians and Indians for hundreds of years for treating vitiligo. The combination of oral psoralens and artificial ultraviolet A (PUVA) therapy was approved for managing severe psoriasis by the Food and Drug Administration in 1982. Since then, PUVA therapy has been an effective modality for treating many cutaneous conditions (psoriasis, atopic dermatitis, vitiligo, and mycosis fungoides). However, proper knowledge and administration of PUVA therapy are vital to treatment success and reducing side effects.
authors.affiliation: University of California-San Francisco, USA.
authors.forename: P B
authors.initials: PB
authors.lastname: McClelland
authors.forename: P
authors.initials: P
authors.lastname: Morgan
authors.forename: E E
authors.initials: EE
authors.lastname: Leach
authors.forename: J
authors.initials: J
authors.lastname: Shelk
mesh_terms: D004509:Education, Nursing, Continuing; D005363:Ficusin / Q000627:therapeutic use*; D006801:Humans; D010778:Photochemotherapy / Q000451:nursing*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy* / Q000451:nursing; D014467:Ultraviolet Therapy / Q000451:nursing*
chemical_list: D017319:Photosensitizing Agents; D005363:Ficusin